Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 19/20 | 0.67 |
| ▸ | PLG | P00747 | 16/20 | 0.67 |
| ▸ | F10 | P00742 | 8/20 | 0.67 |
| ▸ | F2 | P00734 | 7/20 | 0.67 |
| ▸ | ST14 | Q9Y5Y6 | 7/20 | 0.67 |
| ▸ | PLAT | P00750 | 3/20 | 0.67 |
| ▸ | HPN | P05981 | 3/20 | 0.67 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.67 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.67 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2875164 | 0.99 | PLAU (0.65) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2874625 | 0.92 | PLAU (0.80) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL4606324 | 0.91 | PLAU (0.80) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL30912299 | 0.89 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL20674935 | 0.89 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| Upamostat SCHEMBL12618906 | 0.89 | PLAU (0.84) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2880394 | 0.88 | PLAU (0.63) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2875579 | 0.87 | PLAU (0.61) | PLAUPLGF10F2ST14 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3257068 | 0.86 | PLAU (0.52) | PLAUPLGF10F2ST14 | |
| SCHEMBL4588880 | 0.86 | F10 (0.66) | PLAUPLGF10F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100266679-A1 | CRYSTALLINE MODIFICATIONS OF N-ALPHA-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO- (L)- PHENYLALANINE 4-ETHOXYCARBONYLPIPERAZIDE AND/OR SALTS THEREOF | GRUNENBERG ALFONS | 2010-10-21 | — | — | US | claimed |
| US-20080058346-A1 | Crystalline Modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-Hydroxyamidino- (L)- Phenylalanine 4-Ethoxycarbonylpiperazide And/Or Salts Thereof | WILEX AG (DE) | 2008-03-06 | — | — | US | claimed |
| EP-3654979-A1 | USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS | Redhill Biopharma Ltd. (IL) | 2020-05-27 | — | — | EP | disclosed |
| US-20190022088-A1 | USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS | REDHILL BIOPHARMA LTD. (IL) | 2019-01-24 | — | — | US | disclosed |
| WO-2019016595-A1 | USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS | REDHILL BIOPHARMA LTD. (IL) | 2019-01-24 | — | — | WO | disclosed |
| US-8492385-B2 | Crystalline modifications of N-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492385-B2 | Crystalline modifications of N-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2013-07-23 | — | — | US | disclosed |
| US-8492385-B2 | Crystalline modifications of N-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2013-07-23 | — | — | US | disclosed |
| US-7951943-B2 | Method for preparing and purifying 3-hydroxyamidinophenylalanine compounds | WILEX AG (DE) | 2011-05-31 | — | — | US | disclosed |
| US-20100266679-A1 | CRYSTALLINE MODIFICATIONS OF N-ALPHA-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO- (L)- PHENYLALANINE 4-ETHOXYCARBONYLPIPERAZIDE AND/OR SALTS THEREOF | GRUNENBERG ALFONS | 2010-10-21 | — | — | US | disclosed |
| US-20100266679-A1 | CRYSTALLINE MODIFICATIONS OF N-ALPHA-(2,4,6-TRIISOPROPYLPHENYLSULFONYL)-3-HYDROXYAMIDINO- (L)- PHENYLALANINE 4-ETHOXYCARBONYLPIPERAZIDE AND/OR SALTS THEREOF | GRUNENBERG ALFONS | 2010-10-21 | — | — | US | disclosed |
| US-7713980-B2 | Crystalline modifications of N-α-(2,4,6-triisopropyl-phenylsulfonyl)-3-hydroxyamidino-(L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7713980-B2 | Crystalline modifications of N-α-(2,4,6-triisopropyl-phenylsulfonyl)-3-hydroxyamidino-(L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7713980-B2 | Crystalline modifications of N-α-(2,4,6-triisopropyl-phenylsulfonyl)-3-hydroxyamidino-(L)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof | WILEX AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090099360-A9 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080058346-A1 | Crystalline Modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-Hydroxyamidino- (L)- Phenylalanine 4-Ethoxycarbonylpiperazide And/Or Salts Thereof | WILEX AG (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058346-A1 | Crystalline Modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-Hydroxyamidino- (L)- Phenylalanine 4-Ethoxycarbonylpiperazide And/Or Salts Thereof | WILEX AG (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058346-A1 | Crystalline Modifications of N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-Hydroxyamidino- (L)- Phenylalanine 4-Ethoxycarbonylpiperazide And/Or Salts Thereof | WILEX AG (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080039626-A1 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | WILEX AG (DE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099360-A9 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | PEPD, PAH, PRSS3 | PLAU 9/4885PLG 36/4885F10 893/4885 |
| US-20190022088-A1 | USE OF WX-UK1 AND ITS PRODRUG, WX-671, FOR THE TREATMENT OF NON-CANCEROUS MEDICAL CONDITIONS | CTRL, PRSS3, PRSS2 | PLAU 45/4885PLG 521/4885F10 1376/4885 |
| US-20080039626-A1 | Method for Cleaning 3-Hydroxyamidinophenylalanine Derivatives by the Precepitation and Recrystallization of Salt and an Aromatic Sulfonic Acid | PEPD, PAH, PRSS3 | PLAU 9/4885PLG 36/4885F10 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.